{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:32:59Z","timestamp":1793917979414,"version":"4.8.0"},"reference-count":189,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1038\/s41571-024-00956-1","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T08:03:02Z","timestamp":1730448182000},"page":"867-887","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4691-7645","authenticated-orcid":false,"given":"Michele D.","family":"Stanchina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Skye","family":"Montoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey V.","family":"Danilov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9490-7532","authenticated-orcid":false,"given":"Jorge J.","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro J.","family":"Alencar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio C.","family":"Chavez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7988-1565","authenticated-orcid":false,"given":"Chan Y.","family":"Cheah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Chiattone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yucai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3750-7342","authenticated-orcid":false,"given":"Paolo","family":"Ghia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4407-6325","authenticated-orcid":false,"given":"Justin","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2690-3377","authenticated-orcid":false,"given":"Juan Pablo","family":"Alderuccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,1]]},"reference":[{"key":"956_CR1","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s13045-022-01353-w","volume":"15","author":"A Alu","year":"2022","unstructured":"Alu, A., Lei, H., Han, X., Wei, Y. & Wei, X. BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies. J. Hematol. Oncol. 15, 138 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"956_CR2","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41582-023-00800-7","volume":"19","author":"J Kr\u00e4mer","year":"2023","unstructured":"Kr\u00e4mer, J., Bar-Or, A., Turner, T. J. & Wiendl, H. Bruton tyrosine kinase inhibitors for multiple sclerosis. Nat. Rev. Neurol. 19, 289\u2013304 (2023).","journal-title":"Nat. Rev. Neurol."},{"key":"956_CR3","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/cpt.85","volume":"97","author":"Y Wang","year":"2015","unstructured":"Wang, Y., Zhang, L. L., Champlin, R. E. & Wang, M. L. Targeting Bruton\u2019s tyrosine kinase with ibrutinib in B-cell malignancies. Clin. Pharmacol. Ther. 97, 455\u2013468 (2015).","journal-title":"Clin. Pharmacol. Ther."},{"key":"956_CR4","doi-asserted-by":"publisher","first-page":"957","DOI":"10.2217\/fon.14.51","volume":"10","author":"MS Davids","year":"2014","unstructured":"Davids, M. S. & Brown, J. R. Ibrutinib: a first in class covalent inhibitor of Bruton\u2019s tyrosine kinase. Future Oncol. 10, 957\u2013967 (2014).","journal-title":"Future Oncol."},{"key":"956_CR5","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","volume":"31","author":"RH Advani","year":"2012","unstructured":"Advani, R. H. et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies. J. Clin. Oncol. 31, 88\u201394 (2012).","journal-title":"J. Clin. Oncol."},{"key":"956_CR6","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1215637","volume":"369","author":"JC Byrd","year":"2013","unstructured":"Byrd, J. C. et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 369, 32\u201342 (2013).","journal-title":"N. Engl. J. Med."},{"key":"956_CR7","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1400376","volume":"371","author":"JC Byrd","year":"2014","unstructured":"Byrd, J. C. et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N. Engl. J. Med. 371, 213\u2013223 (2014).","journal-title":"N. Engl. J. Med."},{"key":"956_CR8","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","volume":"373","author":"JA Burger","year":"2015","unstructured":"Burger, J. A. et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N. Engl. J. Med. 373, 2425\u20132437 (2015).","journal-title":"N. Engl. J. Med."},{"key":"956_CR9","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","volume":"6","author":"PM Barr","year":"2022","unstructured":"Barr, P. M. et al. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv. 6, 3440\u20133450 (2022).","journal-title":"Blood Adv."},{"key":"956_CR10","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang, M. L. et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 369, 507\u2013516 (2013).","journal-title":"N. Engl. J. Med."},{"key":"956_CR11","doi-asserted-by":"publisher","first-page":"3586","DOI":"10.1158\/1078-0432.CCR-14-2225","volume":"21","author":"RA de Claro","year":"2015","unstructured":"de Claro, R. A. et al. FDA approval: ibrutinib for patients with previously treated mantle cell lymphoma and previously treated chronic lymphocytic leukemia. Clin. Cancer Res. 21, 3586\u20133590 (2015).","journal-title":"Clin. Cancer Res."},{"key":"956_CR12","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","volume":"372","author":"SP Treon","year":"2015","unstructured":"Treon, S. P. et al. Ibrutinib in previously treated Waldenstr\u00f6m\u2019s macroglobulinemia. N. Engl. J. Med. 372, 1430\u20131440 (2015).","journal-title":"N. Engl. J. Med."},{"key":"956_CR13","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1182\/blood-2016-10-747345","volume":"129","author":"A Noy","year":"2017","unstructured":"Noy, A. et al. Targeting Bruton tyrosine kinase with ibrutinib in relapsed\/refractory marginal zone lymphoma. Blood 129, 2224\u20132232 (2017).","journal-title":"Blood"},{"key":"956_CR14","doi-asserted-by":"publisher","first-page":"630942","DOI":"10.3389\/fcell.2021.630942","volume":"9","author":"HY Estupinan","year":"2021","unstructured":"Estupinan, H. Y., Berglof, A., Zain, R. & Smith, C. I. E. Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects. Front. Cell Dev. Biol. 9, 630942 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"956_CR15","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMoa2201817","volume":"386","author":"ML Wang","year":"2022","unstructured":"Wang, M. L. et al. Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma. N. Engl. J. Med. 386, 2482\u20132494 (2022).","journal-title":"N. Engl. J. Med."},{"key":"956_CR16","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","volume":"391","author":"M Wang","year":"2018","unstructured":"Wang, M. et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet 391, 659\u2013667 (2018).","journal-title":"Lancet"},{"key":"956_CR17","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1038\/s41375-019-0575-9","volume":"33","author":"M Wang","year":"2019","unstructured":"Wang, M. et al. Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma. Leukemia 33, 2762\u20132766 (2019).","journal-title":"Leukemia"},{"key":"956_CR18","first-page":"343","volume":"109","author":"S Le Gouill","year":"2024","unstructured":"Le Gouill, S. et al. Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed\/refractory mantle cell lymphoma, including those with poor prognostic factors. Haematologica 109, 343\u2013350 (2024).","journal-title":"Haematologica"},{"key":"956_CR19","unstructured":"Wang, M. et al. Acalabrutinib plus bendamustine and rituximab in untreated mantle cell lymphoma: results from the phase 3, double-blind, placebo-controlled ECHO trial. EHA Library LB3439 https:\/\/library.ehaweb.org\/eha\/2024\/eha2024-congress\/4136515\/michael.wang.acalabrutinib.plus.bendamustine.and.rituximab.in.untreated.mantle.html (2024)."},{"key":"956_CR20","unstructured":"AstraZeneca. Calquence combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO phase III trial. News release. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2024\/calquence-combination-improved-pfs-in-1l-mcl.html (2024)."},{"key":"956_CR21","unstructured":"FDA. FDA grants accelerated approval to zanubrutinib for mantle cell lymphoma. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-zanubrutinib-mantle-cell-lymphoma (2019)."},{"key":"956_CR22","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s13045-021-01174-3","volume":"14","author":"K Zhou","year":"2021","unstructured":"Zhou, K. et al. Zanubrutinib monotherapy in relapsed\/refractory mantle cell lymphoma: a pooled analysis of two clinical trials. J. Hematol. Oncol. 14, 167 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"956_CR23","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1182\/bloodadvances.2020004074","volume":"5","author":"CS Tam","year":"2021","unstructured":"Tam, C. S. et al. Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv. 5, 2577\u20132585 (2021).","journal-title":"Blood Adv."},{"key":"956_CR24","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1182\/blood.2021014162","volume":"139","author":"Y Song","year":"2022","unstructured":"Song, Y. et al. Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. Blood 139, 3148\u20133158 (2022).","journal-title":"Blood"},{"key":"956_CR25","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.3390\/cancers15041018","volume":"15","author":"M Karr","year":"2023","unstructured":"Karr, M. & Roeker, L. A history of targeted therapy development and progress in novel-novel combinations for chronic lymphocytic leukemia (CLL). Cancers 15, 1018 (2023).","journal-title":"Cancers"},{"key":"956_CR26","doi-asserted-by":"publisher","first-page":"100930","DOI":"10.1016\/j.blre.2022.100930","volume":"54","author":"NE Kay","year":"2022","unstructured":"Kay, N. E., Hampel, P. J., Van Dyke, D. L. & Parikh, S. A. CLL update 2022: a continuing evolution in care. Blood Rev. 54, 100930 (2022).","journal-title":"Blood Rev."},{"key":"956_CR27","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.3109\/10428194.2014.957203","volume":"56","author":"O Benjamini","year":"2015","unstructured":"Benjamini, O. et al. Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. Leuk. Lymphoma 56, 1643\u20131650 (2015).","journal-title":"Leuk. Lymphoma"},{"key":"956_CR28","doi-asserted-by":"publisher","first-page":"102307","DOI":"10.1016\/j.eclinm.2023.102307","volume":"65","author":"T Chatzikonstantinou","year":"2023","unstructured":"Chatzikonstantinou, T. et al. Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY. EClinicalMedicine 65, 102307 (2023).","journal-title":"EClinicalMedicine"},{"key":"956_CR29","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/ajh.25638","volume":"94","author":"T Munir","year":"2019","unstructured":"Munir, T. et al. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am. J. Hematol. 94, 1353\u20131363 (2019).","journal-title":"Am. J. Hematol."},{"key":"956_CR30","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1182\/blood-2023-182397","volume":"142","author":"A Itsara","year":"2023","unstructured":"Itsara, A. et al. Long-term outcomes in chronic lymphocytic leukemia treated with ibrutinib: 10-year follow-up of a phase 2 study. Blood 142, 201 (2023).","journal-title":"Blood"},{"key":"956_CR31","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000801","volume":"6","author":"P Ghia","year":"2022","unstructured":"Ghia, P. et al. Acalabrutinib versus investigator\u2019s choice in relapsed\/refractory chronic lymphocytic leukemia: final ASCEND trial results. Hemasphere 6, e801 (2022).","journal-title":"Hemasphere"},{"key":"956_CR32","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/s41375-021-01485-x","volume":"36","author":"JP Sharman","year":"2022","unstructured":"Sharman, J. P. et al. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-na\u00efve chronic lymphocytic leukemia. Leukemia 36, 1171\u20131175 (2022).","journal-title":"Leukemia"},{"key":"956_CR33","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","volume":"395","author":"JP Sharman","year":"2020","unstructured":"Sharman, J. P. et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet 395, 1278\u20131291 (2020).","journal-title":"Lancet"},{"key":"956_CR34","doi-asserted-by":"publisher","first-page":"7539","DOI":"10.1200\/JCO.2022.40.16_suppl.7539","volume":"40","author":"JP Sharman","year":"2022","unstructured":"Sharman, J. P. et al. Acalabrutinib \u00b1 obinutuzumab versus obinutuzumab + chlorambucil in treatment-na\u00efve chronic lymphocytic leukemia: five-year follow-up of ELEVATE-TN. J. Clin. Oncol. 40, 7539 (2022).","journal-title":"J. Clin. Oncol."},{"key":"956_CR35","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1182\/blood-2023-174750","volume":"142","author":"JP Sharman","year":"2023","unstructured":"Sharman, J. P. et al. Acalabrutinib \u00b1 obinutuzumab vs obinutuzumab + chlorambucil in treatment-naive chronic lymphocytic leukemia: 6-year follow-up of elevate-TN. Blood 142, 636 (2023).","journal-title":"Blood"},{"key":"956_CR36","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1182\/bloodadvances.2023011307","volume":"8","author":"MS Davids","year":"2024","unstructured":"Davids, M. S. et al. Acalabrutinib-based regimens in frontline or relapsed\/refractory higher-risk CLL: pooled analysis of 5 clinical trials. Blood Adv. 8, 3345\u20133359 (2024).","journal-title":"Blood Adv."},{"key":"956_CR37","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa2211582","volume":"388","author":"JR Brown","year":"2022","unstructured":"Brown, J. R. et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N. Engl. J. Med. 388, 319\u2013332 (2022).","journal-title":"N. Engl. J. Med."},{"key":"956_CR38","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1182\/blood-2023-174289","volume":"142","author":"JR Brown","year":"2023","unstructured":"Brown, J. R. et al. Extended follow-up of ALPINE randomized phase 3 study confirms sustained superior progression-free survival of zanubrutinib versus ibrutinib for treatment of relapsed\/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R\/R CLL\/SLL). Blood 142, 202 (2023).","journal-title":"Blood"},{"key":"956_CR39","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","volume":"23","author":"CS Tam","year":"2022","unstructured":"Tam, C. S. et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol. 23, 1031\u20131043 (2022).","journal-title":"Lancet Oncol."},{"key":"956_CR40","unstructured":"Ma, S. et al. Combination of zanubrutinib + venetoclax for treatment-naive (TN) CLL\/SLL with del(17p) and\/or TP53: preliminary results from sequoia arm D. EHA Library S160. https:\/\/library.ehaweb.org\/eha\/2024\/eha2024-congress\/422264\/paolo.ghia.combination.of.zanubrutinib.2B.venetoclax.for.treatment-naive.28tn29.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D2%2Asearch%3Dzanubrutinib (2024)."},{"key":"956_CR41","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1200\/JCO.21.01210","volume":"39","author":"JC Byrd","year":"2021","unstructured":"Byrd, J. C. et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J. Clin. Oncol. 39, 3441\u20133452 (2021).","journal-title":"J. Clin. Oncol."},{"key":"956_CR42","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1182\/blood.2022018818","volume":"142","author":"JF Seymour","year":"2023","unstructured":"Seymour, J. F. et al. Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial. Blood 142, 687\u2013699 (2023).","journal-title":"Blood"},{"key":"956_CR43","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1200\/JCO.20.00555","volume":"39","author":"SP Treon","year":"2021","unstructured":"Treon, S. P. et al. Long-term follow-up of ibrutinib monotherapy in symptomatic, previously treated patients with Waldenstrom macroglobulinemia. J. Clin. Oncol. 39, 565\u2013575 (2021).","journal-title":"J. Clin. Oncol."},{"key":"956_CR44","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1111\/bjh.15200","volume":"184","author":"JJ Castillo","year":"2019","unstructured":"Castillo, J. J. et al. Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with Waldenstr\u00f6m macroglobulinaemia. Br. J. Haematol. 184, 1011\u20131014 (2019).","journal-title":"Br. J. Haematol."},{"key":"956_CR45","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1200\/JCO.21.00838","volume":"40","author":"C Buske","year":"2022","unstructured":"Buske, C. et al. Ibrutinib plus rituximab versus placebo plus rituximab for Waldenstr\u00f6m\u2019s macroglobulinemia: final analysis from the randomized phase III iNNOVATE study. J. Clin. Oncol. 40, 52\u201362 (2022).","journal-title":"J. Clin. Oncol."},{"key":"956_CR46","doi-asserted-by":"publisher","first-page":"5099","DOI":"10.1200\/JCO.22.02830","volume":"41","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos, M. A. et al. Zanubrutinib versus ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: final analysis from the randomized phase III ASPEN study. J. Clin. Oncol. 41, 5099\u20135106 (2023).","journal-title":"J. Clin. Oncol."},{"key":"956_CR47","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1182\/blood.2020006844","volume":"136","author":"CS Tam","year":"2020","unstructured":"Tam, C. S. et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study. Blood 136, 2038\u20132050 (2020).","journal-title":"Blood"},{"key":"956_CR48","unstructured":"Abbvie. U.S. FDA approves IMBRUVICA\u00ae (ibrutinib) as first treatment specifically indicated for relapsed\/refractory marginal zone lymphoma (MZL) \u2014 a rare type of non-Hodgkin\u2019s lymphoma. https:\/\/news.abbvie.com\/2017-01-19-U-S-FDA-Approves-IMBRUVICA-ibrutinib-as-First-Treatment-Specifically-Indicated-for-Relapsed-Refractory-Marginal-Zone-Lymphoma-MZL-a-Rare-Type-of-Non-Hodgkins-Lymphoma (2017)."},{"key":"956_CR49","doi-asserted-by":"publisher","first-page":"5773","DOI":"10.1182\/bloodadvances.2020003121","volume":"4","author":"A Noy","year":"2020","unstructured":"Noy, A. et al. Durable ibrutinib responses in relapsed\/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis. Blood Adv. 4, 5773\u20135784 (2020).","journal-title":"Blood Adv."},{"key":"956_CR50","doi-asserted-by":"publisher","first-page":"7141","DOI":"10.1182\/bloodadvances.2023010298","volume":"7","author":"LJ Nastoupil","year":"2023","unstructured":"Nastoupil, L. J. et al. Phase 3 SELENE study: ibrutinib plus BR\/R-CHOP in previously treated patients with follicular or marginal zone lymphoma. Blood Adv. 7, 7141\u20137150 (2023).","journal-title":"Blood Adv."},{"key":"956_CR51","doi-asserted-by":"publisher","first-page":"6323","DOI":"10.1158\/1078-0432.CCR-21-1704","volume":"27","author":"S Opat","year":"2021","unstructured":"Opat, S. et al. The MAGNOLIA trial: zanubrutinib, a next-generation bruton tyrosine kinase inhibitor, demonstrates safety and efficacy in relapsed\/refractory marginal zone lymphoma. Clin. Cancer Res. 27, 6323\u20136332 (2021).","journal-title":"Clin. Cancer Res."},{"key":"956_CR52","doi-asserted-by":"publisher","first-page":"6801","DOI":"10.1182\/bloodadvances.2023010668","volume":"7","author":"S Opat","year":"2023","unstructured":"Opat, S. et al. Safety and efficacy of zanubrutinib in relapsed\/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study. Blood Adv. 7, 6801\u20136811 (2023).","journal-title":"Blood Adv."},{"key":"956_CR53","doi-asserted-by":"publisher","first-page":"4802","DOI":"10.1182\/bloodadvances.2020002183","volume":"4","author":"CS Tam","year":"2020","unstructured":"Tam, C. S. et al. Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma. Blood Adv. 4, 4802\u20134811 (2020).","journal-title":"Blood Adv."},{"key":"956_CR54","doi-asserted-by":"publisher","first-page":"5107","DOI":"10.1200\/JCO.23.00775","volume":"41","author":"PL Zinzani","year":"2023","unstructured":"Zinzani, P. L. et al. ROSEWOOD: a phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma. J. Clin. Oncol. 41, 5107\u20135117 (2023).","journal-title":"J. Clin. Oncol."},{"key":"956_CR55","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1182\/bloodadvances.2022008821","volume":"7","author":"S Bonfiglio","year":"2023","unstructured":"Bonfiglio, S. et al. BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib. Blood Adv. 7, 2794\u20132806 (2023).","journal-title":"Blood Adv."},{"key":"956_CR56","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","volume":"370","author":"JA Woyach","year":"2014","unstructured":"Woyach, J. A. et al. Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib. N. Engl. J. Med. 370, 2286\u20132294 (2014).","journal-title":"N. Engl. J. Med."},{"key":"956_CR57","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","volume":"35","author":"JA Woyach","year":"2017","unstructured":"Woyach, J. A. et al. BTK(C481S)-mediated resistance to ibrutinib in chronic lymphocytic leukemia. J. Clin. Oncol. 35, 1437\u20131443 (2017).","journal-title":"J. Clin. Oncol."},{"key":"956_CR58","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1182\/blood-2016-06-719294","volume":"129","author":"IE Ahn","year":"2017","unstructured":"Ahn, I. E. et al. Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood 129, 1469\u20131479 (2017).","journal-title":"Blood"},{"key":"956_CR59","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/hon.3164_163","volume":"41","author":"JA Woyach","year":"2023","unstructured":"Woyach, J. A. et al. Characterization of mechanisms of resistance in previously treated chronic lymphocytic leukemia (CLL) from a head-to-head trial of acalabrutinib versus ibrutinib. Hematol. Oncol. 41, 249\u2013250 (2023).","journal-title":"Hematol. Oncol."},{"key":"956_CR60","doi-asserted-by":"publisher","first-page":"5589","DOI":"10.1182\/bloodadvances.2022008325","volume":"6","author":"P Blombery","year":"2022","unstructured":"Blombery, P. et al. Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance. Blood Adv. 6, 5589\u20135592 (2022).","journal-title":"Blood Adv."},{"key":"956_CR61","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","volume":"397","author":"AR Mato","year":"2021","unstructured":"Mato, A. R. et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study. Lancet 397, 892\u2013901 (2021).","journal-title":"Lancet"},{"key":"956_CR62","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2300696","volume":"389","author":"AR Mato","year":"2023","unstructured":"Mato, A. R. et al. Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia. N. Engl. J. Med. 389, 33\u201344 (2023).","journal-title":"N. Engl. J. Med."},{"key":"956_CR63","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/blood-2023-183029","volume":"142","author":"EB Gomez","year":"2023","unstructured":"Gomez, E. B. et al. Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor. Blood 142, 62\u201372 (2023).","journal-title":"Blood"},{"key":"956_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00675-9","volume":"12","author":"B Aslan","year":"2022","unstructured":"Aslan, B. et al. Pirtobrutinib inhibits wild-type and mutant Bruton\u2019s tyrosine kinase-mediated signaling in chronic lymphocytic leukemia. Blood Cancer J. 12, 80 (2022).","journal-title":"Blood Cancer J."},{"key":"956_CR65","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","volume":"127","author":"P Martin","year":"2016","unstructured":"Martin, P. et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood 127, 1559\u20131563 (2016).","journal-title":"Blood"},{"key":"956_CR66","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1093\/annonc\/mdv111","volume":"26","author":"CY Cheah","year":"2015","unstructured":"Cheah, C. Y. et al. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann. Oncol. 26, 1175\u20131179 (2015).","journal-title":"Ann. Oncol."},{"key":"956_CR67","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1111\/bjh.18519","volume":"202","author":"G Hess","year":"2023","unstructured":"Hess, G. et al. Real-world experience among patients with relapsed\/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: the SCHOLAR-2 retrospective chart review study. Br. J. Haematol. 202, 749\u2013759 (2023).","journal-title":"Br. J. Haematol."},{"key":"956_CR68","doi-asserted-by":"publisher","first-page":"3988","DOI":"10.1200\/JCO.23.00562","volume":"41","author":"ML Wang","year":"2023","unstructured":"Wang, M. L. et al. Pirtobrutinib in covalent Bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma. J. Clin. Oncol. 41, 3988\u20133997 (2023).","journal-title":"J. Clin. Oncol."},{"key":"956_CR69","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s40265-023-01860-1","volume":"83","author":"SJ Keam","year":"2023","unstructured":"Keam, S. J. Pirtobrutinib: first approval. Drugs 83, 547\u2013553 (2023).","journal-title":"Drugs"},{"key":"956_CR70","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1182\/blood-2023-181627","volume":"142","author":"JB Cohen","year":"2023","unstructured":"Cohen, J. B. et al. Pirtobrutinib in relapsed\/refractory (R\/R) Mantle Cell Lymphoma (MCL) patients with prior cBTKi: safety and efficacy including high-risk subgroup analyses from the phase 1\/2 BRUIN study. Blood 142, 981 (2023).","journal-title":"Blood"},{"key":"956_CR71","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1182\/blood-2023-181108","volume":"142","author":"WG Wierda","year":"2023","unstructured":"Wierda, W. G. et al. Pirtobrutinib in richter transformation: updated efficacy and safety results with 18-month median survival follow-up from the phase 1\/2 BRUIN study. Blood 142, 1737 (2023).","journal-title":"Blood"},{"key":"956_CR72","doi-asserted-by":"publisher","first-page":"3026","DOI":"10.1182\/blood-2023-181309","volume":"142","author":"NN Shah","year":"2023","unstructured":"Shah, N. N. et al. Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in relapsed\/refractory follicular lymphoma: results from the phase 1\/2 BRUIN study. Blood 142, 3026 (2023).","journal-title":"Blood"},{"key":"956_CR73","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1182\/blood-2022-159123","volume":"140","author":"ML Palomba","year":"2022","unstructured":"Palomba, M. L. et al. Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in relapsed\/refractory waldenstr\u00f6m macroglobulinemia: results from the phase 1\/2 BRUIN study. Blood 140, 557\u2013560 (2022).","journal-title":"Blood"},{"key":"956_CR74","doi-asserted-by":"publisher","first-page":"5511","DOI":"10.1039\/D0SC06122K","volume":"12","author":"AT Voice","year":"2021","unstructured":"Voice, A. T., Tresadern, G., Twidale, R. M., van Vlijmen, H. & Mulholland, A. J. Mechanism of covalent binding of ibrutinib to Bruton\u2019s tyrosine kinase revealed by QM\/MM calculations. Chem. Sci. 12, 5511\u20135516 (2021).","journal-title":"Chem. Sci."},{"key":"956_CR75","doi-asserted-by":"publisher","first-page":"694853","DOI":"10.3389\/fimmu.2021.694853","volume":"12","author":"R Zain","year":"2021","unstructured":"Zain, R. & Vihinen, M. Structure-function relationships of covalent and non-covalent BTK inhibitors. Front. Immunol. 12, 694853 (2021).","journal-title":"Front. Immunol."},{"key":"956_CR76","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/hon.2933","volume":"39","author":"H Wang","year":"2021","unstructured":"Wang, H., Zhang, W., Yang, J. & Zhou, K. The resistance mechanisms and treatment strategies of BTK inhibitors in B-cell lymphoma. Hematol. Oncol. 39, 605\u2013615 (2021).","journal-title":"Hematol. Oncol."},{"key":"956_CR77","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.3390\/cancers12051328","volume":"12","author":"B George","year":"2020","unstructured":"George, B. et al. Ibrutinib resistance mechanisms and treatment strategies for B-cell lymphomas. Cancers 12, 1328 (2020).","journal-title":"Cancers"},{"key":"956_CR78","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1182\/blood-2017-01-761726","volume":"129","author":"L Xu","year":"2017","unstructured":"Xu, L. et al. Acquired mutations associated with ibrutinib resistance in Waldenstr\u00f6m macroglobulinemia. Blood 129, 2519\u20132525 (2017).","journal-title":"Blood"},{"key":"956_CR79","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.1111\/bph.14809","volume":"176","author":"F Gui","year":"2019","unstructured":"Gui, F. et al. A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk(C481S) mutation in B-cell malignancies. Br. J. Pharmacol. 176, 4491\u20134509 (2019).","journal-title":"Br. J. Pharmacol."},{"key":"956_CR80","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1038\/s41375-021-01123-6","volume":"35","author":"HY Estupi\u00f1\u00e1n","year":"2021","unstructured":"Estupi\u00f1\u00e1n, H. Y. et al. BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib. Leukemia 35, 1317\u20131329 (2021).","journal-title":"Leukemia"},{"key":"956_CR81","doi-asserted-by":"publisher","first-page":"eadi5798","DOI":"10.1126\/science.adi5798","volume":"383","author":"S Montoya","year":"2024","unstructured":"Montoya, S. et al. Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1\/3 degrader NX-2127. Science 383, eadi5798 (2024).","journal-title":"Science"},{"key":"956_CR82","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1182\/blood-2015-02-626846","volume":"126","author":"T-M Liu","year":"2015","unstructured":"Liu, T.-M. et al. Hypermorphic mutation of phospholipase C, \u03b32 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation. Blood 126, 61\u201368 (2015).","journal-title":"Blood"},{"key":"956_CR83","first-page":"15","volume":"136","author":"ER Thompson","year":"2020","unstructured":"Thompson, E. R. et al. High clonal complexity of resistance mechanisms occurring at progression after single-agent targeted therapy strategies in chronic lymphocytic leukemia. Blood 136, 15\u201316 (2020).","journal-title":"Blood"},{"key":"956_CR84","doi-asserted-by":"publisher","first-page":"894","DOI":"10.3389\/fonc.2020.00894","volume":"10","author":"L Sedlarikova","year":"2020","unstructured":"Sedlarikova, L., Petrackova, A., Papajik, T., Turcsanyi, P. & Kriegova, E. Resistance-associated mutations in chronic lymphocytic leukemia patients treated with novel agents. Front. Oncol. 10, 894 (2020).","journal-title":"Front. Oncol."},{"key":"956_CR85","doi-asserted-by":"publisher","first-page":"5698","DOI":"10.1182\/bloodadvances.2022008955","volume":"7","author":"J Qi","year":"2023","unstructured":"Qi, J. et al. Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors. Blood Adv. 7, 5698\u20135702 (2023).","journal-title":"Blood Adv."},{"key":"956_CR86","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1056\/NEJMoa2114110","volume":"386","author":"E Wang","year":"2022","unstructured":"Wang, E. et al. Mechanisms of resistance to noncovalent Bruton\u2019s tyrosine kinase inhibitors. N. Engl. J. Med. 386, 735\u2013743 (2022).","journal-title":"N. Engl. J. Med."},{"key":"956_CR87","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1182\/bloodadvances.2022008447","volume":"7","author":"A Naeem","year":"2023","unstructured":"Naeem, A. et al. Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance. Blood Adv. 7, 1929\u20131943 (2023).","journal-title":"Blood Adv."},{"key":"956_CR88","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1158\/2643-3230.BCD-21-0131","volume":"2","author":"L Pasqualucci","year":"2021","unstructured":"Pasqualucci, L. Epigenetic rewiring of BCR signaling as a novel mechanism of ibrutinib resistance in ABC-DLBCL. Blood Cancer Discov. 2, 555\u2013558 (2021).","journal-title":"Blood Cancer Discov."},{"key":"956_CR89","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nm.3435","volume":"20","author":"R Rahal","year":"2014","unstructured":"Rahal, R. et al. Pharmacological and genomic profiling identifies NF-\u03baB-targeted treatment strategies for mantle cell lymphoma. Nat. Med. 20, 87\u201392 (2014).","journal-title":"Nat. Med."},{"key":"956_CR90","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/cncr.31831","volume":"125","author":"R Kanagal-Shamanna","year":"2019","unstructured":"Kanagal-Shamanna, R. et al. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. Cancer 125, 559\u2013574 (2019).","journal-title":"Cancer"},{"key":"956_CR91","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1038\/leu.2017.100","volume":"31","author":"A Cosson","year":"2017","unstructured":"Cosson, A. et al. Gain in the short arm of chromosome 2 (2p+) induces gene overexpression and drug resistance in chronic lymphocytic leukemia: analysis of the central role of XPO1. Leukemia 31, 1625\u20131629 (2017).","journal-title":"Leukemia"},{"key":"956_CR92","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11589","volume":"7","author":"JA Burger","year":"2016","unstructured":"Burger, J. A. et al. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat. Commun. 7, 11589 (2016).","journal-title":"Nat. Commun."},{"key":"956_CR93","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02329-y","volume":"8","author":"DA Landau","year":"2017","unstructured":"Landau, D. A. et al. The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy. Nat. Commun. 8, 2185 (2017).","journal-title":"Nat. Commun."},{"key":"956_CR94","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.cell.2009.12.040","volume":"140","author":"SJ Heidorn","year":"2010","unstructured":"Heidorn, S. J. et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209\u2013221 (2010).","journal-title":"Cell"},{"key":"956_CR95","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1182\/blood-2019-123963","volume":"134","author":"G Lazarian","year":"2019","unstructured":"Lazarian, G. et al. B cell restricted expression of mutated IKZF3 modulates BCR signaling and homing pathways in a mouse model of CLL. Blood 134, 848 (2019).","journal-title":"Blood"},{"key":"956_CR96","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1182\/blood.V124.21.297.297","volume":"124","author":"L Mansouri","year":"2014","unstructured":"Mansouri, L. et al. Recurrent mutations within the Nfkbie gene: a novel mechanism for NF-\u03baB deregulation in aggressive chronic lymphocytic leukemia. Blood 124, 297 (2014).","journal-title":"Blood"},{"key":"956_CR97","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1158\/1078-0432.CCR-18-1548","volume":"25","author":"D Asslaber","year":"2019","unstructured":"Asslaber, D. et al. BIRC3 expression predicts CLL progression and defines treatment sensitivity via enhanced NF-\u03baB nuclear translocation. Clin. Cancer Res. 25, 1901\u20131912 (2019).","journal-title":"Clin. Cancer Res."},{"key":"956_CR98","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1182\/blood.V124.21.396.396","volume":"124","author":"J Kuruvilla","year":"2014","unstructured":"Kuruvilla, J. et al. The oral selective inhibitor of nuclear export (SINE) selinexor (KPT-330) demonstrates broad and durable clinical activity in relapsed\/refractory non Hodgkin\u2019s lymphoma (NHL). Blood 124, 396 (2014).","journal-title":"Blood"},{"key":"956_CR99","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13045-017-0412-4","volume":"10","author":"V Camus","year":"2017","unstructured":"Camus, V., Miloudi, H., Taly, A., Sola, B. & Jardin, F. XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy. J. Hematol. Oncol. 10, 47 (2017).","journal-title":"J. Hematol. Oncol."},{"key":"956_CR100","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1158\/2159-8290.CD-19-0298","volume":"9","author":"J Taylor","year":"2019","unstructured":"Taylor, J. et al. Altered nuclear export signal recognition as a driver of oncogenesis. Cancer Discov. 9, 1452\u20131467 (2019).","journal-title":"Cancer Discov."},{"key":"956_CR101","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1038\/ni.1678","volume":"9","author":"S Vallabhapurapu","year":"2008","unstructured":"Vallabhapurapu, S. et al. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-\u03baB signaling. Nat. Immunol. 9, 1364\u20131370 (2008).","journal-title":"Nat. Immunol."},{"key":"956_CR102","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1182\/blood-2017-09-804641","volume":"131","author":"NL Bartlett","year":"2018","unstructured":"Bartlett, N. L. et al. Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. Blood 131, 182\u2013190 (2018).","journal-title":"Blood"},{"key":"956_CR103","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s40164-022-00315-9","volume":"11","author":"H Wang","year":"2022","unstructured":"Wang, H. et al. Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect. Exp. Hematol. Oncol. 11, 60 (2022).","journal-title":"Exp. Hematol. Oncol."},{"key":"956_CR104","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13045-021-01049-7","volume":"14","author":"D Gu","year":"2021","unstructured":"Gu, D., Tang, H., Wu, J., Li, J. & Miao, Y. Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies. J. Hematol. Oncol. 14, 40 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"956_CR105","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/nm.3884","volume":"21","author":"WH Wilson","year":"2015","unstructured":"Wilson, W. H. et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat. Med. 21, 922\u2013926 (2015).","journal-title":"Nat. Med."},{"key":"956_CR106","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.3390\/molecules28052400","volume":"28","author":"D Rozkiewicz","year":"2023","unstructured":"Rozkiewicz, D., Hermanowicz, J. M., Kwiatkowska, I., Krupa, A. & Pawlak, D. Bruton\u2019s tyrosine kinase inhibitors (BTKIs): review of preclinical studies and evaluation of clinical trials. Molecules 28, 2400 (2023).","journal-title":"Molecules"},{"key":"956_CR107","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s40265-020-01318-8","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon, S. Tirabrutinib: first approval. Drugs 80, 835\u2013840 (2020).","journal-title":"Drugs"},{"key":"956_CR108","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1182\/blood-2019-123362","volume":"134","author":"M Nagane","year":"2019","unstructured":"Nagane, M. et al. Phase 1\/2 study of tirabrutinib (ONO\/GS-4059), a next-generation Bruton\u2019s Tyrosine Kinase (BTK) inhibitor, monotherapy in patients with relapsed\/refractory primary central nervous system lymphoma (PCNSL). Blood 134, 1586 (2019).","journal-title":"Blood"},{"key":"956_CR109","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s40265-021-01482-5","volume":"81","author":"S Dhillon","year":"2021","unstructured":"Dhillon, S. Orelabrutinib: first approval. Drugs 81, 503\u2013507 (2021).","journal-title":"Drugs"},{"key":"956_CR110","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/blood-2020-141781","volume":"136","author":"Y Song","year":"2020","unstructured":"Song, Y. et al. Long-term safety and efficacy of orelabrutinib monotherapy in chinese patients with relapsed or refractory mantle cell lymphoma: a multicenter, open-label, phase II study. Blood 136, 1 (2020).","journal-title":"Blood"},{"key":"956_CR111","doi-asserted-by":"publisher","first-page":"4349","DOI":"10.1182\/bloodadvances.2022009168","volume":"7","author":"LJ Deng","year":"2023","unstructured":"Deng, L. J. et al. Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1\/2, open-label, multicenter, single-arm study. Blood Adv. 7, 4349\u20134357 (2023).","journal-title":"Blood Adv."},{"key":"956_CR112","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/ajh.26826","volume":"98","author":"W Xu","year":"2023","unstructured":"Xu, W. et al. Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma patients: multi-center, single-arm, open-label, phase 2 study. Am. J. Hematol. 98, 571\u2013579 (2023).","journal-title":"Am. J. Hematol."},{"key":"956_CR113","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1182\/blood-2021-146491","volume":"138","author":"W Xu","year":"2021","unstructured":"Xu, W. et al. Orelabrutinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma: updated long term results of phase II study. Blood 138, 2638 (2021).","journal-title":"Blood"},{"key":"956_CR114","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-47735-z","volume":"13","author":"SM Goodstal","year":"2023","unstructured":"Goodstal, S. M. et al. Preclinical evidence for the effective use of TL-895, a highly selective and potent second-generation BTK inhibitor, for the treatment of B-cell malignancies. Sci. Rep. 13, 20412 (2023).","journal-title":"Sci. Rep."},{"key":"956_CR115","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1080\/10428194.2021.1913139","volume":"62","author":"W Jurczak","year":"2021","unstructured":"Jurczak, W. et al. Phase I, first-in-human trial of Bruton\u2019s tyrosine kinase inhibitor M7583 in patients with B-cell malignancies. Leuk. Lymphoma 62, 2392\u20132399 (2021).","journal-title":"Leuk. Lymphoma"},{"key":"956_CR116","doi-asserted-by":"publisher","first-page":"4634","DOI":"10.1182\/blood-2023-186517","volume":"142","author":"JC Byrd","year":"2023","unstructured":"Byrd, J. C. et al. A phase (Ph) 2 study of TL-895, a highly selective, novel covalent BTK inhibitor (BTKi), in patients (pts) with treatment-na\u00efve (TN) and relapsed\/refractory (R\/R) BTKi-na\u00efve chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Blood 142, 4634 (2023).","journal-title":"Blood"},{"key":"956_CR117","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/ajh.26888","volume":"98","author":"SF Huntington","year":"2023","unstructured":"Huntington, S. F. et al. DTRMWXHS-12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed\/refractory lymphomas: an open-label, multicenter, phase 1a\/1b study. Am. J. Hematol. 98, 739\u2013749 (2023).","journal-title":"Am. J. Hematol."},{"key":"956_CR118","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1158\/2159-8290.CD-23-0670","volume":"14","author":"JA Woyach","year":"2024","unstructured":"Woyach, J. A. et al. First-in-human study of the reversible BTK inhibitor nemtabrutinib in patients with relapsed\/refractory chronic lymphocytic leukemia and B-cell non-hodgkin lymphoma. Cancer Discov. 14, 66\u201375 (2024).","journal-title":"Cancer Discov."},{"key":"956_CR119","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.3390\/genes14122182","volume":"14","author":"A Chirino","year":"2023","unstructured":"Chirino, A., Montoya, S., Safronenka, A. & Taylor, J. Resisting the resistance: navigating BTK mutations in chronic lymphocytic leukemia (CLL). Genes 14, 2182 (2023).","journal-title":"Genes"},{"key":"956_CR120","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04684-1","volume":"13","author":"E Thieme","year":"2022","unstructured":"Thieme, E. et al. Dual BTK\/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma. Cell Death Dis. 13, 246 (2022).","journal-title":"Cell Death Dis."},{"key":"956_CR121","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1158\/1535-7163.MCT-21-0832","volume":"21","author":"WG Rice","year":"2022","unstructured":"Rice, W. G. et al. Luxeptinib (CG-806) targets FLT3 and clusters of kinases operative in acute myeloid leukemia. Mol. Cancer Ther. 21, 1125\u20131135 (2022).","journal-title":"Mol. Cancer Ther."},{"key":"956_CR122","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1182\/blood-2020-141495","volume":"136","author":"R Bejar","year":"2020","unstructured":"Bejar, R. et al. A Phase 1 a\/b dose escalation study of the mutation agnostic BTK\/FLT3 inhibitor CG-806 in patients with relapsed or refractory CLL\/SLL or non-hodgkin\u2019s lymphomas. Blood 136, 35 (2020).","journal-title":"Blood"},{"key":"956_CR123","doi-asserted-by":"publisher","first-page":"5953","DOI":"10.1182\/blood-2023-181151","volume":"142","author":"AD Goldberg","year":"2023","unstructured":"Goldberg, A. D. et al. A phase 1a\/b trial of luxeptinib (CG-806) in patients with relapsed\/refractory B-cell malignancies or acute myeloid leukemia and evaluation of new G3 formulation. Blood 142, 5953 (2023).","journal-title":"Blood"},{"key":"956_CR124","doi-asserted-by":"publisher","first-page":"4400","DOI":"10.1182\/blood-2023-180485","volume":"142","author":"Y Song","year":"2023","unstructured":"Song, Y. et al. A novel dual covalent and non-covalent next generation inhibitor of Bruton\u2019s tyrosine kinase LP-168 in patients with relapsed\/refractory B cell non-hodgkin lymphoma: safety and efficacy results from a phase 1 study. Blood 142, 4400 (2023).","journal-title":"Blood"},{"key":"956_CR125","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1182\/blood-2023-186432","volume":"142","author":"JA Woyach","year":"2023","unstructured":"Woyach, J. A. et al. Initial results of a phase 1 dose escalation study of LP-168, a novel covalent and non-covalent next-generation inhibitor of Bruton\u2019s tyrosine kinase. Blood 142, 328 (2023).","journal-title":"Blood"},{"key":"956_CR126","doi-asserted-by":"publisher","first-page":"4020","DOI":"10.1158\/1538-7445.AM2023-4020","volume":"83","author":"L Wang","year":"2023","unstructured":"Wang, L. et al. Abstract 4020: HMPL-760 is a highly potent and selective reversible BTK inhibitor, targeting BTK and BTKC481S in B-cell malignancies. Cancer Res. 83, 4020 (2023).","journal-title":"Cancer Res."},{"key":"956_CR127","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1182\/bloodadvances.2024012706","volume":"8","author":"HY Estupi\u00f1\u00e1n","year":"2024","unstructured":"Estupi\u00f1\u00e1n, H. Y. et al. In BTK, phosphorylated Y223 in the SH3 domain mirrors catalytic activity, but does not influence biological function. Blood Adv. 8, 1981\u20131990 (2024).","journal-title":"Blood Adv."},{"key":"956_CR128","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1021\/acs.jmedchem.3c01007","volume":"67","author":"DW Robbins","year":"2024","unstructured":"Robbins, D. W. et al. Discovery and preclinical pharmacology of NX-2127, an orally bioavailable degrader of Bruton\u2019s tyrosine kinase with immunomodulatory activity for the treatment of patients with B cell malignancies. J. Med. Chem. 67, 2321\u20132336 (2024).","journal-title":"J. Med. Chem."},{"key":"956_CR129","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1182\/blood-2022-164772","volume":"140","author":"AR Mato","year":"2022","unstructured":"Mato, A. R. et al. NX-2127-001, a first-in-human trial of NX-2127, a Bruton\u2019s tyrosine kinase-targeted protein degrader, in patients with relapsed or refractory chronic lymphocytic leukemia and B-cell malignancies. Blood 140, 2329\u20132332 (2022).","journal-title":"Blood"},{"key":"956_CR130","doi-asserted-by":"publisher","first-page":"4463","DOI":"10.1182\/blood-2023-179872","volume":"142","author":"A Danilov","year":"2023","unstructured":"Danilov, A. et al. A first-in-human phase 1 trial of NX-2127, a first-in-class Bruton\u2019s tyrosine kinase (BTK) dual-targeted protein degrader with immunomodulatory activity, in patients with relapsed\/refractory B cell malignancies. Blood 142, 4463 (2023).","journal-title":"Blood"},{"key":"956_CR131","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1182\/blood-2021-147473","volume":"138","author":"DW Robbins","year":"2021","unstructured":"Robbins, D. W. et al. Nx-5948, a selective degrader of BTK with activity in preclinical models of hematologic and brain malignancies. Blood 138, 2251 (2021).","journal-title":"Blood"},{"key":"956_CR132","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1182\/blood-2023-179508","volume":"142","author":"FF Searle E","year":"2023","unstructured":"Searle E, F. F. et al. Initial findings from a first-in-human phase 1a\/b trial of NX-5948, a selective Bruton\u2019s tyrosine kinase (BTK) degrader, in patients with relapsed\/refractory B cell malignancies. Blood 142, 4473 (2023).","journal-title":"Blood"},{"key":"956_CR133","unstructured":"Linton, K. et al. Latest results from an ongoing first-in-human phase 1A\/B study of NX-5948, a selective Bruton\u2019s tyrosine kinase (BTK) degrader, in patients with relapsed\/refractory CLL and other B-cell malignancies. EHA Library S155. https:\/\/library.ehaweb.org\/eha\/2024\/eha2024-congress\/422259\/kim.linton.latest.results.from.an.ongoing.first-in-human.phase.1a.b.study.of.html?f=menu%3D6*browseby%3D8*sortby%3D2*ce_id%3D2552*ot_id%3D29194*marker%3D5099*featured%3D18498 (2024)."},{"key":"956_CR134","doi-asserted-by":"publisher","first-page":"4401","DOI":"10.1182\/blood-2023-180109","volume":"142","author":"JF Seymour","year":"2023","unstructured":"Seymour, J. F. et al. First results from a phase 1, first-in-human study of the Bruton\u2019s tyrosine kinase (BTK) degrader Bgb-16673 in patients (Pts) with relapsed or refractory (R\/R) B-cell malignancies (BGB-16673-101). Blood 142, 4401 (2023).","journal-title":"Blood"},{"key":"956_CR135","unstructured":"Parrondo, R. et al. Preliminary efficacy and safety of the Bruton Tyrosine Kinase (BTK) degrader BGB-16673 in patients with relapsed or refractory CLL\/SLL: results from the phase 1 BGB-16673-101 study. EHA Library S157. https:\/\/library.ehaweb.org\/eha\/2024\/eha2024-congress\/422261\/ricardo.parrondo.preliminary.efficacy.and.safety.of.the.bruton.tyrosine.kinase.html?f=menu%3D6*browseby%3D8*sortby%3D2*ce_id%3D2552*ot_id%3D29194*marker%3D5099*featured%3D18498 (2024)."},{"key":"956_CR136","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1182\/blood-2021-153146","volume":"138","author":"JA Woyach","year":"2021","unstructured":"Woyach, J. A. et al. Long-term results of alliance A041202 show continued advantage of ibrutinib-based regimens compared with bendamustine plus rituximab (BR) chemoimmunotherapy. Blood 138, 639 (2021).","journal-title":"Blood"},{"key":"956_CR137","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","volume":"379","author":"JA Woyach","year":"2018","unstructured":"Woyach, J. A. et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N. Engl. J. Med. 379, 2517\u20132528 (2018).","journal-title":"N. Engl. J. Med."},{"key":"956_CR138","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1182\/blood-2018-10-879429","volume":"133","author":"JA Burger","year":"2019","unstructured":"Burger, J. A. et al. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood 133, 1011\u20131019 (2019).","journal-title":"Blood"},{"key":"956_CR139","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1182\/blood.2021014960","volume":"140","author":"TD Shanafelt","year":"2022","unstructured":"Shanafelt, T. D. et al. Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood 140, 112\u2013120 (2022).","journal-title":"Blood"},{"key":"956_CR140","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1056\/NEJMoa1817073","volume":"381","author":"TD Shanafelt","year":"2019","unstructured":"Shanafelt, T. D. et al. Ibrutinib\u2013rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N. Engl. J. Med. 381, 432\u2013443 (2019).","journal-title":"N. Engl. J. Med."},{"key":"956_CR141","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S1470-2045(23)00144-4","volume":"24","author":"P Hillmen","year":"2023","unstructured":"Hillmen, P. et al. Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 24, 535\u2013552 (2023).","journal-title":"Lancet Oncol."},{"key":"956_CR142","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","volume":"20","author":"C Moreno","year":"2019","unstructured":"Moreno, C. et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 20, 43\u201356 (2019).","journal-title":"Lancet Oncol."},{"key":"956_CR143","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1053\/j.seminhematol.2024.01.015","volume":"61","author":"IE Ahn","year":"2024","unstructured":"Ahn, I. E. & Davids, M. S. Therapeutic targeting of apoptosis in chronic lymphocytic leukemia. Semin. Hematol. 61, 109\u2013118 (2024).","journal-title":"Semin. Hematol."},{"key":"956_CR144","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","volume":"378","author":"JF Seymour","year":"2018","unstructured":"Seymour, J. F. et al. Venetoclax\u2013rituximab in relapsed or refractory chronic lymphocytic leukemia. N. Engl. J. Med. 378, 1107\u20131120 (2018).","journal-title":"N. Engl. J. Med."},{"key":"956_CR145","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","volume":"21","author":"O Al-Sawaf","year":"2020","unstructured":"Al-Sawaf, O. et al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 21, 1188\u20131200 (2020).","journal-title":"Lancet Oncol."},{"key":"956_CR146","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1200\/JCO.2017.76.6840","volume":"36","author":"S Stilgenbauer","year":"2018","unstructured":"Stilgenbauer, S. et al. Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial. J. Clin. Oncol. 36, 1973\u20131980 (2018).","journal-title":"J. Clin. Oncol."},{"key":"956_CR147","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts, A. W. et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 374, 311\u2013322 (2016).","journal-title":"N. Engl. J. Med."},{"key":"956_CR148","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1182\/blood-2014-09-603670","volume":"125","author":"P Jain","year":"2015","unstructured":"Jain, P. et al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood 125, 2062\u20132067 (2015).","journal-title":"Blood"},{"key":"956_CR149","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00467-7","volume":"11","author":"N Timofeeva","year":"2021","unstructured":"Timofeeva, N. & Gandhi, V. Ibrutinib combinations in CLL therapy: scientific rationale and clinical results. Blood Cancer J. 11, 79 (2021).","journal-title":"Blood Cancer J."},{"key":"956_CR150","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","volume":"380","author":"N Jain","year":"2019","unstructured":"Jain, N. et al. Ibrutinib and venetoclax for first-line treatment of CLL. N. Engl. J. Med. 380, 2095\u20132103 (2019).","journal-title":"N. Engl. J. Med."},{"key":"956_CR151","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1182\/blood-2017-10-810044","volume":"131","author":"S O\u2019Brien","year":"2018","unstructured":"O\u2019Brien, S. et al. Single-agent ibrutinib in treatment-na\u00efve and relapsed\/refractory chronic lymphocytic leukemia: a 5-year experience. Blood 131, 1910\u20131919 (2018).","journal-title":"Blood"},{"key":"956_CR152","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1001\/jamaoncol.2021.1649","volume":"7","author":"N Jain","year":"2021","unstructured":"Jain, N. et al. Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: a nonrandomized phase 2 trial. JAMA Oncol. 7, 1213\u20131219 (2021).","journal-title":"JAMA Oncol."},{"key":"956_CR153","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1200\/JCO.21.00807","volume":"39","author":"WG Wierda","year":"2021","unstructured":"Wierda, W. G. et al. Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study. J. Clin. Oncol. 39, 3853\u20133865 (2021).","journal-title":"J. Clin. Oncol."},{"key":"956_CR154","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1182\/blood.2021014488","volume":"139","author":"CS Tam","year":"2022","unstructured":"Tam, C. S. et al. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. Blood 139, 3278\u20133289 (2022).","journal-title":"Blood"},{"key":"956_CR155","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1182\/blood-2023-187128","volume":"142","author":"P Ghia","year":"2023","unstructured":"Ghia, P. et al. Relapse after first-line fixed duration ibrutinib + venetoclax: high response rates to ibrutinib retreatment and absence of BTK mutations in patients with chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL) with up to 5 years of follow-up in the phase 2 captivate study. Blood 142, 633 (2023).","journal-title":"Blood"},{"key":"956_CR156","doi-asserted-by":"publisher","unstructured":"Barr, P. et al. Fixed-duration ibrutinib + venetoclax for first-line treatment of chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL): 4-y follow-up from the FD cohort of the phase 2 CAPTIVATE study. J. Clin. Oncol. 41, https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.7535 (2023).","DOI":"10.1200\/JCO.2023.41.16_suppl.7535"},{"key":"956_CR157","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1182\/blood-2023-177713","volume":"142","author":"C Moreno","year":"2023","unstructured":"Moreno, C. et al. First-line fixed-duration ibrutinib plus venetoclax (Ibr+Ven) versus chlorambucil plus obinutuzumab (Clb+O): 55-month follow-up from the glow study. Blood 142, 634 (2023).","journal-title":"Blood"},{"key":"956_CR158","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S1470-2045(23)00452-7","volume":"24","author":"CU Niemann","year":"2023","unstructured":"Niemann, C. U. et al. Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 24, 1423\u20131433 (2023).","journal-title":"Lancet Oncol."},{"key":"956_CR159","doi-asserted-by":"publisher","first-page":"EVIDoa2200006","DOI":"10.1056\/EVIDoa2200006","volume":"1","author":"AP Kater","year":"2022","unstructured":"Kater, A. P. et al. Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities. NEJM Evid. 1, EVIDoa2200006 (2022).","journal-title":"NEJM Evid."},{"key":"956_CR160","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa2310063","volume":"390","author":"T Munir","year":"2024","unstructured":"Munir, T. et al. Chronic lymphocytic leukemia therapy guided by measurable residual disease. N. Engl. J. Med. 390, 326\u2013337 (2024).","journal-title":"N. Engl. J. Med."},{"key":"956_CR161","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1182\/blood-2021-144336","volume":"138","author":"A Tedeschi","year":"2021","unstructured":"Tedeschi, A. et al. Zanubrutinib in combination with venetoclax for patients with treatment-na\u00efve (TN) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with del(17p): early results from arm D of the SEQUOIA (BGB-3111-304) trial. Blood 138, 67 (2021).","journal-title":"Blood"},{"key":"956_CR162","doi-asserted-by":"publisher","first-page":"7500","DOI":"10.1200\/JCO.2023.41.16_suppl.7500","volume":"41","author":"JA Woyach","year":"2023","unstructured":"Woyach, J. A. et al. Results of a phase 3 study of IVO vs IO for previously untreated older patients (pts) with chronic lymphocytic leukemia (CLL) and impact of COVID-19 (Alliance). J. Clin. Oncol. 41, 7500 (2023).","journal-title":"J. Clin. Oncol."},{"key":"956_CR163","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","volume":"388","author":"B Eichhorst","year":"2023","unstructured":"Eichhorst, B. et al. First-line venetoclax combinations in chronic lymphocytic leukemia. N. Engl. J. Med. 388, 1739\u20131754 (2023).","journal-title":"N. Engl. J. Med."},{"key":"956_CR164","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1182\/blood-2023-181090","volume":"142","author":"LE Roeker","year":"2023","unstructured":"Roeker, L. E. et al. Fixed-duration pirtobrutinib combined with venetoclax \u00b1 rituximab in relapsed\/refractory chronic lymphocytic leukemia: updated results, including MRD data, from the BRUIN phase 1b study. Blood 142, 3269 (2023).","journal-title":"Blood"},{"key":"956_CR165","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/hon.3163_153","volume":"41","author":"J Soumerai","year":"2023","unstructured":"Soumerai, J. et al. Long\u2010term follow\u2010up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVEN) in previously untreated patients with CLL\/SLL. Hematol. Oncol. 41, 233\u2013235 (2023).","journal-title":"Hematol. Oncol."},{"key":"956_CR166","doi-asserted-by":"publisher","first-page":"e879","DOI":"10.1016\/S2352-3026(21)00307-0","volume":"8","author":"JD Soumerai","year":"2021","unstructured":"Soumerai, J. D. et al. Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Haematol. 8, e879\u2013e890 (2021).","journal-title":"Lancet Haematol."},{"key":"956_CR167","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1016\/S1470-2045(21)00455-1","volume":"22","author":"MS Davids","year":"2021","unstructured":"Davids, M. S. et al. Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study. Lancet Oncol. 22, 1391\u20131402 (2021).","journal-title":"Lancet Oncol."},{"key":"956_CR168","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/S1470-2045(21)00638-0","volume":"23","author":"ML Wang","year":"2022","unstructured":"Wang, M. L. et al. Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (<\/=65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. Lancet Oncol. 23, 406\u2013415 (2022).","journal-title":"Lancet Oncol."},{"key":"956_CR169","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1182\/blood-2023-181312","volume":"142","author":"P Jain","year":"2023","unstructured":"Jain, P. et al. Six years follow up of ibrutinib plus rituximab (IR) followed by short course R-hyper CVAD\/MTX in patients (age \u2264 65 years) with previously untreated mantle cell lymphoma \u2014 phase-II window-1 clinical trial. Blood 142, 1688 (2023).","journal-title":"Blood"},{"key":"956_CR170","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1182\/blood-2021-153390","volume":"138","author":"M Wang","year":"2021","unstructured":"Wang, M. et al. Ibrutinib plus rituximab and venetoclax (IRV) followed by risk-stratified observation or short course R-Hypercvad\/MTX in young patients with previously untreated mantle cell lymphoma \u2014 phase-II window-2 clinical trial. Blood 138, 3525 (2021).","journal-title":"Blood"},{"key":"956_CR171","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/S0140-6736(24)00184-3","volume":"403","author":"M Dreyling","year":"2024","unstructured":"Dreyling, M. et al. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. Lancet 403, 2293\u20132306 (2024).","journal-title":"Lancet"},{"key":"956_CR172","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1200\/JCO.21.01797","volume":"40","author":"P Jain","year":"2022","unstructured":"Jain, P. et al. Ibrutinib with rituximab in first-line treatment of older patients with mantle cell lymphoma. J. Clin. Oncol. 40, 202\u2013212 (2022).","journal-title":"J. Clin. Oncol."},{"key":"956_CR173","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1182\/blood-2023-180069","volume":"142","author":"A Kumar","year":"2023","unstructured":"Kumar, A. et al. A multicenter phase 2 trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in patients with treatment-na\u00efve, TP53-mutant mantle cell lymphoma. Blood 142, 738\u2013738 (2023).","journal-title":"Blood"},{"key":"956_CR174","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1182\/blood-2022-158656","volume":"140","author":"J Ruan","year":"2022","unstructured":"Ruan, J. et al. Phase 2 Trial of acalabrutinib-lenalidomide-rituximab (ALR) with real-time monitoring of MRD in patients with treatment-na\u00efve mantle cell lymphoma. Blood 140, 175\u2013177 (2022).","journal-title":"Blood"},{"key":"956_CR175","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1200\/JCO.21.02370","volume":"41","author":"M Wang","year":"2023","unstructured":"Wang, M. et al. Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. J. Clin. Oncol. 41, 555\u2013567 (2023).","journal-title":"J. Clin. Oncol."},{"key":"956_CR176","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1007\/s11912-022-01286-0","volume":"24","author":"JL Munoz","year":"2022","unstructured":"Munoz, J. L., Wang, Y., Jain, P. & Wang, M. BTK inhibitors and CAR T-cell therapy in treating mantle cell lymphoma-finding a dancing partner. Curr. Oncol. Rep. 24, 1299\u20131311 (2022).","journal-title":"Curr. Oncol. Rep."},{"key":"956_CR177","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.jcyt.2023.03.005","volume":"25","author":"W Luo","year":"2023","unstructured":"Luo, W. et al. Bruton tyrosine kinase inhibitors preserve anti-CD19 chimeric antigen receptor T-cell functionality and reprogram tumor micro-environment in B-cell lymphoma. Cytotherapy 25, 739\u2013749 (2023).","journal-title":"Cytotherapy"},{"key":"956_CR178","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1182\/blood.2023021306","volume":"143","author":"A Minson","year":"2024","unstructured":"Minson, A. et al. CAR T cells and time-limited ibrutinib as treatment for relapsed\/refractory mantle cell lymphoma: the phase 2 TARMAC study. Blood 143, 673\u2013684 (2024).","journal-title":"Blood"},{"key":"956_CR179","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/S1470-2045(14)70311-0","volume":"15","author":"A Younes","year":"2014","unstructured":"Younes, A. et al. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. Lancet Oncol. 15, 1019\u20131026 (2014).","journal-title":"Lancet Oncol."},{"key":"956_CR180","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1200\/JCO.18.02403","volume":"37","author":"A Younes","year":"2019","unstructured":"Younes, A. et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. J. Clin. Oncol. 37, 1285\u20131295 (2019).","journal-title":"J. Clin. Oncol."},{"key":"956_CR181","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/j.ccell.2021.10.006","volume":"39","author":"WH Wilson","year":"2021","unstructured":"Wilson, W. H. et al. Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. Cancer Cell 39, 1643\u20131653.e3 (2021).","journal-title":"Cancer Cell"},{"key":"956_CR182","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1200\/JCO.23.01574","volume":"42","author":"A Cooper","year":"2024","unstructured":"Cooper, A. et al. CD5 gene signature identifies diffuse large B-cell lymphomas sensitive to Bruton\u2019s tyrosine kinase inhibition. J. Clin. Oncol. 42, 467\u2013480 (2024).","journal-title":"J. Clin. Oncol."},{"key":"956_CR183","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ejca.2019.05.024","volume":"117","author":"C Soussain","year":"2019","unstructured":"Soussain, C. et al. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: final analysis of the phase II \u2018proof-of-concept\u2019 iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network. Eur. J. Cancer 117, 121\u2013130 (2019).","journal-title":"Eur. J. Cancer"},{"key":"956_CR184","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1158\/2159-8290.CD-17-0613","volume":"7","author":"C Grommes","year":"2017","unstructured":"Grommes, C. et al. Ibrutinib unmasks critical role of bruton tyrosine kinase in primary CNS lymphoma. Cancer Discov. 7, 1018\u20131029 (2017).","journal-title":"Cancer Discov."},{"key":"956_CR185","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1182\/blood-2022-157001","volume":"140","author":"C Grommes","year":"2022","unstructured":"Grommes, C. et al. Phase Ib\/II trial of the Bruton\u2019s tyrosine kinase (BTK) inhibitor, ibrutinib, in combination with rituximab and lenalidomide in refractory\/recurrent primary (PCNSL) and secondary central nervous system lymphoma (SCNSL). Blood 140, 3807\u20133808 (2022).","journal-title":"Blood"},{"key":"956_CR186","doi-asserted-by":"publisher","first-page":"6275","DOI":"10.1182\/blood-2023-186488","volume":"142","author":"A Perez Perez","year":"2023","unstructured":"Perez Perez, A. et al. Rituximab ibrutinib lenalidomide (R2I) combination for primary or secondary large B-cell CNS lymphoma: last resort or bridge to cellular therapy? Blood 142, 6275 (2023).","journal-title":"Blood"},{"key":"956_CR187","doi-asserted-by":"publisher","first-page":"4195","DOI":"10.1182\/blood-2018-99-112184","volume":"132","author":"M Roschewski","year":"2018","unstructured":"Roschewski, M. et al. Dose-adjusted teddi-R induces durable complete remissions in relapsed and refractory primary CNS lymphoma. Blood 132, 4195 (2018).","journal-title":"Blood"},{"key":"956_CR188","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1182\/blood-2023-177994","volume":"142","author":"J Simard","year":"2023","unstructured":"Simard, J. et al. Phase 2 response-adapted study of ibrutinib with temozolomide, etoposide, liposomal doxorubicin, dexamethasone, and rituximab (TEDDI-R) for secondary CNS lymphoma. Blood 142, 854 (2023).","journal-title":"Blood"},{"key":"956_CR189","unstructured":"Rosa, K. Continued maintenance with obinutuzumab plus acalabrutinib\/venetoclax boosts uMRD rate in R\/R CLL. https:\/\/www.onclive.com\/view\/continued-maintenance-with-obinutuzumab-plus-acalabrutinib-venetoclax-boosts-umrd-rate-in-r-r-cll (2023)."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-024-00956-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-024-00956-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-024-00956-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T09:03:57Z","timestamp":1732007037000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-024-00956-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":189,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["956"],"URL":"https:\/\/doi.org\/10.1038\/s41571-024-00956-1","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,1]]},"assertion":[{"value":"2 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.V.D. has received research funding and consultancy fees from Abbvie, AstraZeneca, Beigene, Bristol Myers Squibb, GenMab, Lilly Oncology, MEI Pharma, Nurix Therapeutics and Presage; research funding from Bayer, Cyclacel and Incyte; and consultancy fees from Genentech, Janssen, Merck and Regeneron. J.J.C. reports consulting or advisory roles for AbbVie\/Pharmacyclics, BeiGene, Cellectar, Janssen, Kite Pharma\/Gilead, Loxo Oncology\/Lilly, Mustang Bio and Roche\/Genentech, and institutional research funding from AbbVie, AstraZeneca, BeiGene, Cellectar, Loxo\/Lilly, Pharmacyclics and TG Therapeutics. A.J.A. has received consultancy fees from Amgen, BeiGene, Epizyme, Genentech, Incyte, Janssen, Kite, Lilly, Seagen, and TG Therapeutics and research funding from BeiGene, Incyte and Loxo Oncology. J.C.C. has received consultancy fees from AbbVie, ADC Therapeutics, Adicet, AstraZeneca, BeiGene, Bristol Myers Squibb, Cellectar, Genentech, Genmab, Janssen, Kite Pharma\/Gilead and Novartis; honoraria from AstraZeneca, BeiGene and Lilly; research funding from AstraZeneca, Janssen and Merck; and has served as a Data and Safety Monitoring Board member for Atara and the National Cancer Institute. C.Y.C. has received consultancy fees or honoraria from AbbVie, AstraZeneca, BeiGene, Bristol Myers Squibb, Dizal, Genmab, Gilead, Janssen, Lilly, Menarini, Novartis, Roche, and TG Therapeutics and research funding from AbbVie, Bristol Myers Squibb, Lilly, MSD and Roche. Y.W. has received institutional research funding from Genentech, Genmab, Incyte, InnoCare, Lilly, Loxo Oncology, MorphoSys, and Novartis and institutional honoraria from Kite Pharma; has served on advisory boards (compensation to institution) for AstraZeneca, BeiGene, Incyte, InnoCare, Jansen, Kite Pharma\/Gilead, Lilly, Loxo Oncology and TG Therapeutics; has consulted for (compensation to institution) AbbVie and Innocare; and has an immediate family member who is employed by and has stock ownership in Merck. M.T. has received consultancy fees from AstraZeneca, Loxo Oncology\/Lilly and Pharmacyclics\/Janssen; honoraria from the Brazilian Association of Hematology, Hemotherapy and Cellular Therapy, Curio Science, Dava Oncology, Intellisphere, the Massachusetts Medical Society, MJH Life Sciences, and VJHemOnc and institutional research funding from Abbvie, AstraZeneca, Beigene, Genentech, Genmab and Nurix Therapeutics. P.G. has received honoraria from AbbVie, ArQule\/MSD, AstraZeneca, BeiGene, Celgene\/Juno\/Bristol Myers Squibb, Janssen, Loxo Oncology\/Lilly, MEI Pharma, Roche, and Sanofi and research funding from AbbVie, AstraZeneca, Bristol Myers Squibb, Janssen and Sunesis. J.P.A. has received consultancy fees from AbbVie, ADC Therapeutics, Genentech, and Regeneron and research funding from AbbVie, ADC Therapeutics, BeiGene and Genmab. M.D.S., S.M., C.C. and J.T. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}